NCT06581159View on ClinicalTrials.gov

Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 23, 2025

Primary Completion Date

July 29, 2025

Study Completion Date

July 29, 2025

Conditions
Heart Failure With Preserved Ejection FractionPulmonary Hypertension
Interventions
BIOLOGICAL

HS135

Subcutaneous Injection

OTHER

Placebo

Subcutaneous Injection

Trial Locations (2)

64111

Site-105, Kansas City

85016

Site-104, Phoenix

Sponsors

Lead Sponsor

35Pharma Inc
All Listed Sponsors
lead

35Pharma Inc

INDUSTRY